FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

,			,	 -	
Vashington	DC 2	0549			

on, D.C. 20549		

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bur	den								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Cavanaugh Sarah</u>			2. Issuer Name <b>and</b> Ticker or Trading Symbol Celldex Therapeutics, Inc. [ CLDX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner							
(Last)	`	irst) ERAPEUTICS,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/15/2023					2	X Officer (give title below) Other (spe below)  SVP OF CORP AFFAIRS & ADMI						
53 FRONTAGE ROAD, SUITE 220				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) HAMPT	ON N.	J	08827												led by Mor		orting Persor n One Repor	
(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication																		
									icate that a trai defense condi						on or written	plan th	nat is intended	i to
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,		Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Benefici	s Formula (D) (O) (I) (I) (I)		m: Direct or Indirect Enstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code V Amount (A) or (D)		Price		action(s)			msu. 4)							
		٦	Γable II - D (e						uired, Dis s, options,					Owned				
1. Title of 2. 3. Transaction 3A. Deemed 4. Derivative Conversion Date Execution Date, Tr		ransact code (In:	ansaction of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	is Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				c	Code	v	(A)		Date Exercisable	Exp Dat	piration te	Title	Amount or Number of Shares					
Incentive Stock Option (right to buy) <sup>(1)</sup>	\$36.87	06/15/2023 <sup>(1)</sup>			A		75,000		06/15/2024 <sup>(2)</sup>	06/:	15/2033	Common Stock	75,000	\$0	75,000	)	D	

## **Explanation of Responses:**

- 1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
- 2.25% vest on June 15,2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

/s/ Sam Martin, attorney-in-fact 06/20/2023 for Sarah Cavanaugh

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.